Future studies are needed to determine whether the route and dosing of bifunctional anti-PD-L1/IL-15 superagonists, delivered subcutaneously, or of immunotherapies delivered directly into the tumor can modulate the immune system to convert treatment-refractory patients into responders. Here, IL15 is linked to neoplasm.